Abstract
SummarySummaryTwenty, mostly premenopausal, patients suffering from fibrocystic mastopathy were enrolled in a pilot study of a monthly injection of goserelin depot, an LH-RH agonist. This hormone treatment inhibits the hypothalamopituitary axis in premenopausal as well as in postmenopausal women and caused improvement in subjective complaints and objective clinical and radiological signs of mastopathy in this group of patients. LH-RH agonists might represent a useful new approach to the treatment of this syndrome and warrant further clinical investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
